Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin in CADASIL (CERICA)
NCT05755997Phase 2Active, not recruiting
- Sponsor
- EVER Pharma
- Start
- Nov 2023
- Primary completion
- Mar 2026
- Modality
- Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cerebrolysin in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), sponsored by EVER Pharma. Started Nov 2023; status: active, not recruiting.
02
Drugs
cerebrolysin
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on NCT05755997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05755997.